CN106414500B - 抗-wt1/hla双特异性抗体 - Google Patents

抗-wt1/hla双特异性抗体 Download PDF

Info

Publication number
CN106414500B
CN106414500B CN201480061156.9A CN201480061156A CN106414500B CN 106414500 B CN106414500 B CN 106414500B CN 201480061156 A CN201480061156 A CN 201480061156A CN 106414500 B CN106414500 B CN 106414500B
Authority
CN
China
Prior art keywords
cells
cell
seq
tumor
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480061156.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN106414500A (zh
Inventor
D·沙因伯格
向京宜
陶道
言甦
刘诚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Eureka Therapeutics Inc
Original Assignee
Memorial Sloan Kettering Cancer Center
Eureka Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center, Eureka Therapeutics Inc filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN106414500A publication Critical patent/CN106414500A/zh
Application granted granted Critical
Publication of CN106414500B publication Critical patent/CN106414500B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201480061156.9A 2013-11-07 2014-11-07 抗-wt1/hla双特异性抗体 Expired - Fee Related CN106414500B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361901310P 2013-11-07 2013-11-07
US61/901,310 2013-11-07
US201462037875P 2014-08-15 2014-08-15
US62/037,875 2014-08-15
PCT/US2014/064621 WO2015070061A1 (en) 2013-11-07 2014-11-07 Anti-wt1/hla bi-specific antibody

Publications (2)

Publication Number Publication Date
CN106414500A CN106414500A (zh) 2017-02-15
CN106414500B true CN106414500B (zh) 2020-04-10

Family

ID=51987482

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480061156.9A Expired - Fee Related CN106414500B (zh) 2013-11-07 2014-11-07 抗-wt1/hla双特异性抗体

Country Status (5)

Country Link
EP (1) EP3066130B1 (enExample)
JP (1) JP6553069B2 (enExample)
CN (1) CN106414500B (enExample)
ES (1) ES2742224T3 (enExample)
WO (1) WO2015070061A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
HK1258444A1 (zh) 2015-10-09 2019-11-15 Immatics Biotechnologies Gmbh 抗wt1/hla特异性抗体
WO2017070608A1 (en) 2015-10-23 2017-04-27 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides
EP4491234A3 (en) 2017-02-08 2025-04-09 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017197A2 (pt) 2017-02-20 2020-04-14 Dragonfly Therapeutics, Inc. proteínas que se ligam a her2, nkg2d e cd16
CN110741016A (zh) 2017-04-26 2020-01-31 优瑞科生物技术公司 嵌合抗体/t-细胞受体构筑体及其用途
US12178830B2 (en) 2017-06-30 2024-12-31 Memorial Sloan Kettering Cancer Center Compositions and methods for adoptive cell therapy for cancer
JP7072792B2 (ja) * 2017-12-11 2022-05-23 国立大学法人神戸大学 二重特異性抗体
EP3728317A2 (en) 2017-12-21 2020-10-28 F. Hoffmann-La Roche AG Antibodies binding to hla-a2/wt1
PE20220278A1 (es) 2018-02-08 2022-02-25 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d
AU2019218125B2 (en) 2018-02-08 2025-03-13 Dragonfly Therapeutics, Inc. Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells
WO2019161133A1 (en) 2018-02-15 2019-08-22 Memorial Sloan Kettering Cancer Center Foxp3 targeting agent compositions and methods of use for adoptive cell therapy
TW201942134A (zh) 2018-02-20 2019-11-01 美商蜻蜓醫療公司 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法
CA3100775A1 (en) * 2018-05-18 2019-11-21 Children's National Medical Center Improved targeted t-cell therapy
KR20250112921A (ko) 2018-08-08 2025-07-24 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
US20240383999A1 (en) * 2020-04-02 2024-11-21 The Board Of Regents Of The University Of Texas System Cd5l-binding antibodies and uses for the same
EP4146271A4 (en) 2020-05-06 2024-09-04 Dragonfly Therapeutics, Inc. PROTEINS THAT BIND NKG2D, CD16 AND CLEC12A
EP4216998A1 (en) * 2020-09-24 2023-08-02 F. Hoffmann-La Roche AG Prevention or mitigation of t-cell bispecific antibody-related adverse effects
CN116635064A (zh) 2020-12-18 2023-08-22 世纪治疗股份有限公司 具有适应性受体特异性的嵌合抗原受体系统
US12377144B2 (en) 2021-03-03 2025-08-05 Dragonfly Therapeutics, Inc. Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen
KR20240158351A (ko) * 2022-03-22 2024-11-04 모르포시스 아게 Cd3에 특이적인 탈면역화 항체

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100453556C (zh) * 2003-10-16 2009-01-21 麦克罗梅特股份公司 多特异性的去免疫化cd3结合物
CN101426521A (zh) * 2005-12-21 2009-05-06 医疗免疫有限责任公司 EPHA2 BiTE分子及其应用
WO2012135854A2 (en) * 2011-04-01 2012-10-04 Memorial Sloan-Kettering Cancer Center Antibodies to cytosolic peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100453556C (zh) * 2003-10-16 2009-01-21 麦克罗梅特股份公司 多特异性的去免疫化cd3结合物
CN101426521A (zh) * 2005-12-21 2009-05-06 医疗免疫有限责任公司 EPHA2 BiTE分子及其应用
WO2012135854A2 (en) * 2011-04-01 2012-10-04 Memorial Sloan-Kettering Cancer Center Antibodies to cytosolic peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Therapeutic antibodies to intracellular targets in cancer therapy";Nicholas Veomett, Tao Dao & David A Scheinberg;《Expert Opinion on Biological Therapy》;20130831;第13卷(第11期);参见2.2，3.1 *

Also Published As

Publication number Publication date
ES2742224T3 (es) 2020-02-13
EP3066130B1 (en) 2019-05-15
EP3066130A1 (en) 2016-09-14
CN106414500A (zh) 2017-02-15
JP6553069B2 (ja) 2019-07-31
WO2015070061A1 (en) 2015-05-14
JP2017500057A (ja) 2017-01-05

Similar Documents

Publication Publication Date Title
CN106414500B (zh) 抗-wt1/hla双特异性抗体
KR102844265B1 (ko) 항-cd24 조성물 및 이의 용도
KR102664891B1 (ko) Pd-l1 및 lag-3에 결합하는 결합 분자
AU2016263808B2 (en) Trispecific binding proteins and methods of use
US10239952B2 (en) Anti-WT1/HLA bi-specific antibody
JP2022068296A (ja) 抗ｃｄ１１２ｒ組成物及び方法
US20220323600A1 (en) Teac and attac immunooncology compositions and methods
KR20210031479A (ko) Cd137 및 ox40에 결합하는 항체 분자
US10934331B2 (en) Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells
CN110049779A (zh) 抗体-药物缀合物和免疫检查点抑制剂的组合
ES2717308T3 (es) Células madre pluri- o multi-potentes genéticamente modificadas y sus usos
KR20190109574A (ko) 암 치료를 위한 항-fam19a5 항체의 용도
JP2020505438A (ja) インテグリン結合性ポリペプチド−Ｆｃ融合タンパク質および免疫調節物質を用いる併用がん治療法
CN117321087A (zh) 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质
KR20180100412A (ko) 면역강화제에 의해 증진되는 초항원 매개된 암 면역요법
JP2023532807A (ja) Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
US20230132241A1 (en) Antigen binding proteins specifically binding prame
JP2023502091A (ja) 免疫療法のための組成物及び方法
KR20160135764A (ko) 이중-특이적 항원-결합 폴리펩티드
KR20220150274A (ko) Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
KR20190117467A (ko) IFN-γ-유도성 조절 T 세포 전환가능 항암 (IRTCA) 항체 및 그의 용도
JP2022546364A (ja) キメラ抗原受容体系及びその使用
Tunheim et al. Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates
KR20220070440A (ko) 치료학적 항체와 인터루킨-2 (il2)를 수반한 치료
HK1227903A1 (en) Anti-wt1/hla bi-specific antibody

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20200410